Release Date: June 25, 2026
Valid for Credit through: June 24, 2027
Program Overview:
This CME/CE program will review current clinical data and practical applications for anti-CD20 therapeutics in the treatment of relapsing multiple sclerosis. Expert neuroinflammatory disease faculty, Drs. Fred D. Lublin and Joseph R. Berger, will critically examine the role of B cells in MS pathogenesis, the development of anti-CD20 monoclonal antibodies to selectively target and deplete CD20-expressing B cells, and the key differences among therapeutic available agents in this class. The faculty will discuss and contextualize pivotal clinical trial data (including OPERA, ORATORIO, ASCLEPIOS, and ULTIMATE), with attention to relapse reduction, MRI outcomes, disability progression, and NEDA-3 results. The lecture will also address safety considerations, including infusion reactions, infections, hypogammaglobulinemia, vigor of vaccine response, pregnancy and breastfeeding guidance, and recommended screening before treatment. To conclude, the faculty will highlight current best practices for distinguishing among anti-CD20 therapies to improve outcomes in patients with MS.
Target Audience
MS specialists, other neurologists, and other healthcare professionals involved in the management of patients with multiple sclerosis
Learning Objectives:
- Review strategies to assess individualized patient characteristics and disease prognosis to determine the role of CD20 in treatment planning
- Develop treatment plans to delay disability and progression in patients with RMS
- Review and analyze clinical trial data for CD20 therapeutics to manage patients with RMS
Course Faculty
Joseph R. Berger, MD, FACP, FAAN, FANA
Professor of Neurology Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA
Fred D. Lublin, MD
Saunders Family Professor of Neurology Director
Director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Icahn School of Medicine at Mount Sinai
New York, NY
Provided by:
